Key points
- Record revenue of $74.2 million, up 153% from the previous year
- Profit from ordinary activities after tax increased by 214%
- Net tangible assets per security increased by 146%
- No dividends have been paid or are proposed
- The company is not a foreign entity
Full summary
BLS Pharmaceuticals Ltd has released its Annual Report for the year ended 30 June 2026, highlighting substantial growth across various financial metrics. The company reported a 153% increase in revenue from ordinary activities, reaching $74.2 million, and a 214% rise in profit from ordinary activities after tax to $15.397 million. Net tangible assets per security also saw a significant increase, rising by 146% to $0.133. The company did not propose any dividends for the year. BLS Pharmaceuticals Ltd remains focused on disciplined capital allocation and continues to assess acquisition and investment opportunities to complement its existing platform.
Guidance
Revenue of $74.2 million and Adjusted EBITDA of $19.0 million in FY26
Outlook
BLS Pharmaceuticals Ltd is entering FY27 with more manufacturing capacity, better market access, bigger contracts and more opportunities than ever before. The company plans to execute on existing contracts, bring its UK manufacturing facility online, expand into new international markets, continue investing in proprietary medicines and intellectual property, and build the clinical and commercial evidence needed to unlock the potential of its medicines.